{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:56:29Z","timestamp":1781646989417,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cachexia is a multifactorial syndrome associated with impaired physiologic reserve and adverse outcomes in advanced NSCLC. Its relationship with early toxicity and survival during EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy remains insufficiently characterized. We evaluated the impact of baseline cachexia on toxicity and clinical outcomes in patients with EGFR-mutated stage III\u2013IV NSCLC treated with EGFR-TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>In this retrospective cohort, 247 consecutive patients treated with EGFR-TKIs were included. Cachexia was defined using the Fearon international consensus criteria. Hematologic and selected non-hematologic adverse events were recorded during the first four months of therapy. Associations with hematologic toxicity were assessed using logistic regression, and progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan\u2013Meier methods and Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Baseline cachexia was present in 91 patients (37%). Cachectic patients more frequently had KPS &lt;90 (44% vs 27%) and liver metastases (19% vs 5.8%). Overall hematologic toxicity was higher among cachectic versus non-cachectic patients (85.7% vs 69.9%), driven mainly by anemia (40% vs 21%) and lymphopenia (74% vs 56%). Cachexia independently predicted hematologic toxicity (adjusted OR 2.26, 95% CI 1.15\u20134.68) and worse OS (adjusted HR 1.65, 95% CI 1.07\u20132.57); median OS was 37.22 months in cachectic patients versus 45.80 months in non-cachectic patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Baseline cachexia was associated with a higher burden of early hematologic toxicity and independently worse OS in EGFR-mutated advanced NSCLC treated with EGFR-TKIs. Routine baseline identification may help prioritize early supportive care and closer monitoring during the initial months of therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15773-1","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:06:55Z","timestamp":1775117215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS"],"prefix":"10.1186","volume":"26","author":[{"given":"Jenny G.","family":"Turcott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5982-2795","authenticated-orcid":false,"given":"Cittim B.","family":"Palomares-Palomares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-1671","authenticated-orcid":false,"given":"Eduardo","family":"Rios-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cardenas-Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Diaz-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvador Guti\u00e9rrez","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Arrieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"4","key":"15773_CR1","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41591-023-02232-8","volume":"29","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat Med. 2023;29(4):846\u201358.","journal-title":"Nat Med"},{"key":"15773_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103305","volume":"160","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2021;160:103305.","journal-title":"Crit Rev Oncol Hematol"},{"key":"15773_CR3","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192396","volume":"15","author":"D Cardenas-Fernandez","year":"2023","unstructured":"Cardenas-Fernandez D, Soberanis Pina P, Turcott JG, Chavez-Tapia N, Conde-Flores E, Cardona AF, et al. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma. Ther Adv Med Oncol. 2023;15:17588359231192396.","journal-title":"Ther Adv Med Oncol"},{"key":"15773_CR4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","volume":"143","author":"B Roch","year":"2020","unstructured":"Roch B, Coffy A, Jean-Baptiste S, Palaysi E, Daures J-P, Pujol J-L, et al. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors. Lung Cancer. 2020;143:19\u201326.","journal-title":"Lung Cancer"},{"issue":"1","key":"15773_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331.","journal-title":"Age Ageing"},{"key":"15773_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/601434","volume":"2011","author":"CL Donohoe","year":"2011","unstructured":"Donohoe CL, Ryan AM, Reynolds JV. Cancer cachexia: mechanisms and clinical implications. Gastroenterol Res Pract. 2011;2011:1\u201313.","journal-title":"Gastroenterol Res Pract"},{"key":"15773_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1113875","volume":"10","author":"J Lyu","year":"2023","unstructured":"Lyu J, Yang N, Xiao L, Nie X, Xiong J, Liu Y, et al. Prognostic value of sarcopenia in patients with lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors or immune checkpoint inhibitors. Front Nutr. 2023;10:1113875.","journal-title":"Front Nutr"},{"issue":"5","key":"15773_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395.","journal-title":"Lancet Oncol"},{"issue":"3","key":"15773_CR9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/jcsm.13216","volume":"14","author":"T Shukuya","year":"2023","unstructured":"Shukuya T, Takahashi K, Shintani Y, Miura K, Sekine I, Takayama K, et al. Epidemiology, risk factors and impact of cachexia on patient outcome: results from the Japanese Lung Cancer Registry Study. J Cachexia Sarcopenia Muscle. 2023;14(3):1274\u201385.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"4","key":"15773_CR10","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/SPC.0000000000000450","volume":"13","author":"SM Chowdhry","year":"2019","unstructured":"Chowdhry SM, Chowdhry VK. Cancer cachexia and treatment toxicity. Curr Opin Support Palliat Care. 2019;13(4):292\u20137.","journal-title":"Curr Opin Support Palliat Care"},{"key":"15773_CR11","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.2147\/CMAR.S261585","volume":"12","author":"J Ni","year":"2020","unstructured":"Ni J, Zhang L. Cancer Cachexia: Definition, Staging, and Emerging Treatments. Cancer Manag Res. 2020;12:5597\u2013605.","journal-title":"Cancer Manag Res"},{"key":"15773_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-50","volume":"10","author":"O Arrieta","year":"2010","unstructured":"Arrieta O, Michel Ortega RM, Villanueva-Rodriguez G, Serna-Thome MG, Flores-Estrada D, Diaz-Romero C, et al. Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study. BMC Cancer. 2010;10:50.","journal-title":"BMC Cancer"},{"issue":"12","key":"15773_CR13","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41416-021-01519-2","volume":"125","author":"R Rosell","year":"2021","unstructured":"Rosell R, Cardona AF, Arrieta O, Aguilar A, Ito M, Pedraz C, et al. Coregulation of pathways in lung cancer patients with EGFR mutation: therapeutic opportunities. Br J Cancer. 2021;125(12):1602\u201311.","journal-title":"Br J Cancer"},{"issue":"8","key":"15773_CR14","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1634\/theoncologist.2015-0058","volume":"20","author":"O Arrieta","year":"2015","unstructured":"Arrieta O, la De Torre-Vallejo M, L\u00f3pez-Mac\u00edas D, Orta D, Turcott J, Macedo-P\u00e9rez E-O, et al. Nutritional status, body surface, and low lean body mass\/body mass index are related to dose reduction and severe gastrointestinal toxicity induced by afatinib in patients with non-small cell lung cancer. Oncologist. 2015;20(8):967\u201374.","journal-title":"Oncologist"},{"issue":"2","key":"15773_CR15","doi-asserted-by":"publisher","first-page":"502","DOI":"10.4143\/crt.2018.117","volume":"51","author":"Y Kim","year":"2019","unstructured":"Kim Y, Lee S-H, Ahn JS, Ahn M-J, Park K, Sun J-M. Efficacy and safety of afatinib for EGFR-mutant non-small cell lung cancer, compared with gefitinib or erlotinib. Cancer Res Treat. 2019;51(2):502\u20139.","journal-title":"Cancer Res Treat"},{"key":"15773_CR16","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2018.06.032","volume":"123","author":"CH Suh","year":"2018","unstructured":"Suh CH, Park HS, Kim KW, Pyo J, Hatabu H, Nishino M. Pneumonitis in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitor: meta-analysis of 153 cohorts with 15,713 patients: meta-analysis of incidence and risk factors of EGFR-TKI pneumonitis in NSCLC. Lung Cancer. 2018;123:60\u20139.","journal-title":"Lung Cancer"},{"issue":"2","key":"15773_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113\u201325.","journal-title":"N Engl J Med"},{"issue":"4","key":"15773_CR18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/1759-7714.14674","volume":"14","author":"JW Chang","year":"2023","unstructured":"Chang JW, Chang CF, Huang CY, Yang CT, Kuo CS, Fang YF, et al. The survival after discontinuation of EGFR-TKIs due to intolerable adverse events in patients with EGFR-mutated non-small cell lung cancer. Thorac Cancer. 2023;14(4):348\u201356.","journal-title":"Thorac Cancer"},{"issue":"9","key":"15773_CR19","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.841","volume":"5","author":"M Shiono","year":"2016","unstructured":"Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, et al. An analysis of the relationship between metastases and cachexia in lung cancer patients. Cancer Med. 2016;5(9):2641\u20138.","journal-title":"Cancer Med"},{"issue":"25","key":"15773_CR20","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1111\/1759-7714.15017","volume":"14","author":"CT Wu","year":"2023","unstructured":"Wu CT, Hsu PC, Chang JW, Chang CF, Huang CY, Yang CT, et al. Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib. Thorac Cancer. 2023;14(25):2548\u201357.","journal-title":"Thorac Cancer"},{"issue":"4","key":"15773_CR21","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/1759-7714.13018","volume":"10","author":"T Ono","year":"2019","unstructured":"Ono T, Igawa S, Ozawa T, Kasajima M, Ishihara M, Hiyoshi Y, et al. Evaluation of osimertinib efficacy according to body surface area and body mass index in patients with non-small cell lung cancer harboring an EGFR mutation: a prospective observational study. Thorac Cancer. 2019;10(4):880\u20139.","journal-title":"Thorac Cancer"},{"key":"15773_CR22","doi-asserted-by":"publisher","unstructured":"BartolomeoV, Jongbloed M, van de Worp WRPH, Langen R, Degens J, Hendriks LEL, de Ruysscher DKM. Cachexia and Sarcopenia in Oligometastatic Non-Small Cell Lung Cancer: Making a Potential Curable Disease Incurable? Cancers (Basel). 2024;16(1):230. https:\/\/doi.org\/10.3390\/cancers16010230.","DOI":"10.3390\/cancers16010230"},{"issue":"5","key":"15773_CR23","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CMM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33(5):997\u20131006.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"12","key":"15773_CR24","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.trecan.2018.10.001","volume":"4","author":"SF Schmidt","year":"2018","unstructured":"Schmidt SF, Rohm M, Herzig S, Berriel Diaz M. Cancer cachexia: more than skeletal muscle wasting. Trends Cancer. 2018;4(12):849\u201360.","journal-title":"Trends Cancer"},{"key":"15773_CR25","doi-asserted-by":"crossref","unstructured":"Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, Ripamonti CI, E.G.C.E.a. clinicalguidelines@esmo.org, Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines(\u2606), ESMO Open. 2021;6(3);100092.","DOI":"10.1016\/j.esmoop.2021.100092"},{"issue":"21","key":"15773_CR26","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1200\/JCO.20.00611","volume":"38","author":"EJ Roeland","year":"2020","unstructured":"Roeland EJ, Bohlke K, Baracos VE, Bruera E, Fabbro ED, Dixon S, et al. Management of cancer cachexia: ASCO guideline. J Clin Oncol. 2020;38(21):2438\u201353.","journal-title":"J Clin Oncol"},{"key":"15773_CR27","doi-asserted-by":"crossref","unstructured":"Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: clinical nutrition in cancer. Clin Nutr. 2021;40(5):2898\u2013913.","DOI":"10.1016\/j.clnu.2021.02.005"},{"issue":"24","key":"15773_CR28","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","volume":"391","author":"JD Groarke","year":"2024","unstructured":"Groarke JD, Crawford J, Collins SM, Lubaczewski S, Roeland EJ, Naito T, et al. Ponsegromab for the treatment of cancer cachexia. N Engl J Med. 2024;391(24):2291\u2013303.","journal-title":"N Engl J Med"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15773-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15773-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:23:19Z","timestamp":1781644999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15773-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15773"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15773-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"26 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Comit\u00e9 de \u00c9tica en Investigaci\u00f3n of the Instituto Nacional de Cancerolog\u00eda (INCan), Mexico City (approval No. 2024\/068), and was conducted in accordance with the Declaration of Helsinki. The requirement for informed consent was waived due to the study's retrospective design.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"631"}}